Dr. Vaibhav Agrawal, MD

Dr. Agrawal practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Agrawal's NPI, 1538402565, was assigned on March 27, 2013. Dr. Agrawal graduated from Chicago Medical School at Rosalind Franklin University of Medicine and Science in 2013. Dr. Agrawal holds California license A168278.

Dr. Agrawal's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Agrawal's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Agrawal to 1 more other site and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Agrawal practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Agrawal's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Agrawal is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Agrawal's licenses on file in 4 states: California, Illinois, Indiana and Pennsylvania.

Dmand AI lists chronic anemia, deep vein thrombosis (DVT) and immune deficiency disease among the conditions Dr. Agrawal treats.

CMS data shows 1,042 Medicare services from Dr. Agrawal across 5 procedure codes in 2024, for 164 Medicare patients. Medicare paid $97,245 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 164 Medicare patients who saw Dr. Agrawal in 2024. The largest group is 65 to 74, with 89 patients. 75% of them have high blood pressure, and 67% have high cholesterol. 31% are also on Medicaid. Their average risk score is 3.89, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Agrawal's median patient age at 64, with 42% women.

In 2024, Dr. Agrawal wrote 272 Medicare Part D claims for 29 patients. 81% of them were for generic drugs. CMS names the drug for 120 of them, across 5 drugs with 11 or more claims each, at $353,993 in total drug cost. In 2023, CMS named 63 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Agrawal for performance year 2024, reported as part of a group. Dr. Agrawal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Agrawal as offering telehealth.

Dmand AI links 62 papers to Dr. Agrawal, published from 2018 to 2025. 2024 was the busiest year, with 17. The most frequent topics are Hematopoietic Stem Cell Transplantation, Precursor Cell Lymphoblastic Leukemia-Lymphoma and Graft vs Host Disease. Dr. Agrawal has published most often in Blood Adv. Dr. Agrawal's most frequent co-authors are Hoda Pourhassan, Vinod Pullarkat, MD and Anthony S. Stein, MD.

Dmand AI links Dr. Agrawal to 3 clinical trials. 3 are still active or recruiting. Conditions studied include Myelodysplastic Syndromes, Neoplasm, Residual and Primary Myelofibrosis. City of Hope Medical Center sponsors the most, 2.

CMS Open Payments shows 27 general payments to Dr. Agrawal from 18 drug and device companies from 2017 to 2025. Speaker and faculty fees make up the largest share, 66% of the total. Jazz Pharmaceuticals Inc. paid the most, $3,243.

Dr. Agrawal graduated from Chicago Medical School at Rosalind Franklin University of Medicine and Science in 2013. Dr. Agrawal is a member of AAP, AAPL, ACP, AMA, ASCO and ASH.

Dr. Agrawal is in network with 12 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.